Zhuhai Rundu Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Zhuhai Rundu Pharmaceutical's earnings have been declining at an average annual rate of -10.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 0.3% per year. Zhuhai Rundu Pharmaceutical's return on equity is 3.4%, and it has net margins of 3.1%.
Key information
-10.1%
Earnings growth rate
-10.0%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | -0.3% |
Return on equity | 3.4% |
Net Margin | 3.1% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Zhuhai Rundu Pharmaceutical's (SZSE:002923) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 04There May Be Reason For Hope In Zhuhai Rundu Pharmaceutical's (SZSE:002923) Disappointing Earnings
May 05Recent updates
Zhuhai Rundu Pharmaceutical's (SZSE:002923) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 04Zhuhai Rundu Pharmaceutical's (SZSE:002923) Dividend Is Being Reduced To CN¥0.20
May 29There May Be Reason For Hope In Zhuhai Rundu Pharmaceutical's (SZSE:002923) Disappointing Earnings
May 05There's Reason For Concern Over Zhuhai Rundu Pharmaceutical Co., Ltd.'s (SZSE:002923) Massive 32% Price Jump
Mar 05Revenue & Expenses Breakdown
How Zhuhai Rundu Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 1,224 | 39 | 324 | 147 |
30 Jun 24 | 1,234 | 35 | 359 | 144 |
31 Mar 24 | 1,239 | 56 | 381 | 132 |
31 Dec 23 | 1,292 | 67 | 392 | 127 |
30 Sep 23 | 1,326 | 119 | 415 | 108 |
30 Jun 23 | 1,369 | 150 | 420 | 94 |
31 Mar 23 | 1,409 | 158 | 439 | 91 |
01 Jan 23 | 1,372 | 155 | 462 | 92 |
30 Sep 22 | 1,319 | 153 | 471 | 86 |
30 Jun 22 | 1,274 | 150 | 476 | 90 |
31 Mar 22 | 1,189 | 143 | 462 | 87 |
01 Jan 22 | 1,190 | 140 | 476 | 84 |
30 Sep 21 | 1,157 | 114 | 475 | 83 |
30 Jun 21 | 1,172 | 124 | 475 | 81 |
31 Mar 21 | 1,259 | 139 | 522 | 88 |
31 Dec 20 | 1,253 | 136 | 528 | 94 |
30 Sep 20 | 1,299 | 131 | 612 | 105 |
30 Jun 20 | 1,324 | 130 | 666 | 105 |
31 Mar 20 | 1,337 | 122 | 712 | 104 |
31 Dec 19 | 1,360 | 119 | 745 | 115 |
30 Sep 19 | 1,312 | 125 | 737 | 105 |
30 Jun 19 | 1,258 | 120 | 717 | 101 |
31 Mar 19 | 1,162 | 116 | 664 | 90 |
01 Jan 19 | 1,044 | 107 | 608 | 66 |
30 Sep 18 | 970 | 103 | 514 | 87 |
30 Jun 18 | 884 | 97 | 439 | 67 |
31 Mar 18 | 816 | 92 | 382 | 55 |
31 Dec 17 | 779 | 91 | 347 | 45 |
31 Dec 16 | 652 | 87 | 319 | 0 |
31 Dec 15 | 578 | 71 | 294 | 0 |
31 Dec 14 | 524 | 60 | 272 | 0 |
31 Dec 13 | 434 | 59 | 217 | 0 |
Quality Earnings: 002923 has a large one-off gain of CN¥20.7M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 002923's current net profit margins (3.1%) are lower than last year (9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002923's earnings have declined by 10.1% per year over the past 5 years.
Accelerating Growth: 002923's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002923 had negative earnings growth (-67.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 002923's Return on Equity (3.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 01:04 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhuhai Rundu Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|